Early and late responses to treatment with either oral (600 mg/day) or intravenous (20 mg/day) (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (aminohydroxypropylidene bisphosphonate; APD) were studied in 142 patients with Paget's disease of bone who had not previously been treated with bisphosphonate. The efficacy of three therapeutic regimens was compared: (a) oral aminohydroxypropylidene bisphosphonate given continuously until six months after the serum alkaline phosphatase activity had returned to normal (long term); (b) oral aminohydroxypropylidene bisphosphonate given until urinary hydroxyproline excretion had returned to normal (short term); (c) intravenous aminohydroxypropylidene bisphosphonate for 10 days. With either oral or intravenous treatment the decrease in urinary hydroxyproline excretion was rapid and always preceded the fall in serum alkaline phosphatase activity. Normal urinary hydroxyproline excretion is essential for return of the serum alkaline phosphatase activity to normal. Complete biochemical remission, defined as return of the serum alkaline phosphatase activity to normal, was obtained in 129 patients (91%). The
Introduction
Bisphosphonates have been successfully used to treat conditions characterised by increased bone resorption.' Among those more widely used in clinical practice, aminohydroxypropylidene bisphosphonate ((3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate; APD) is very potent and has produced excellent results in Paget's disease of bone and malignant hypercalcaemia and in more rare diseases such as juvenile osteoporosis and Gaucher's disease affecting bone. [2] [3] [4] [5] [6] [7] We have shown that aminohydroxypropylidene bisphosphonate predictably suppresses the activity of Paget's disease and induces long term clinical and biochemical remission. 8 In this report we compare the efficacy of three different therapeutic regimens in 142 patients with active Paget's disease.
Patients and methods
Between July 1977 and July 1985, 142 out of 162 consecutive patients with Paget's disease of bone who had not previously been given bisphosphonate fulfilled the following criteria: raised serum alkaline phosphatase activity; uniform treatment with aminohydroxypropylidene bisphosphonate; and follow up for at least four months. Eighty six ofthe patients were men and 56 women and their ages ranged from 26 to 85 years (median 63). The diagnosis was based on scintigraphic, radiological, and biochemical criteria and in 102 cases it was confirmed histologically.9 The number of lesions per patient ranged from one to 40, roughly half the patients having one (n= 51) or two (n=29). In 113 cases the patients had not previously received specific treatment, and in the remaining 29 calcitonin had been stopped three months to three years (median 10 months) before beginning aminohydroxypropylidene bisphosphonate.
Treatment regimens-Three different treatment modalities were used: (a) 600 mg aminohydroxypropylidene bisphosphonate by mouth daily, continued for six months after the serum alkaline phosphatase activity had returned to normal (long term treatment); (b) 600 mg by mouth daily continued until urinary hydroxyproline excretion returned to normal (short term treatment); and (c) 20 mg daily given by intravenous infusion for 10 days. Long term treatment as defined above was changed to short term when it was realised that serum alkaline phosphatase activity returns to normal after urinary hydroxyproline excretion; intravenous treatment was used as soon as the preparation became available. This study was therefore retrospective and, though it was not a formal randomised therapeutic trial, the patients included in each treatment modality were consecutive and unselected. Oral aminohydroxypropylidene bisphosphonate was prepared in gelatin capsules, liquid form, or enteric coated tablets and given two or three times daily half an hour before meals. The dose was chosen on the basis of findings in animals. 10 
Changes in body temperature
About half the patients treated with either oral (n=43; 54%) or intravenous (n=20; 63%) aminohydroxypropylidene bisphosphonate had a transient increase in body temperature exceeding 0-50C (fig 2) . The peak increase occurred within the first 72 hours of treatment and was generally accompanied by mild complaints such as malaise and myalgias, which did not require analgesics. After this rise the temperature quickly decreased toward baseline.
In those patients who had a rise in body temperature a transient significant increase in urinary hydroxyproline excretion was also noted on the first day of treatment (fig 2) . This was more pronounced with intravenous (n=20; t= 2-93, p<0 01) than with oral (n=43; t=2-35, p<0 05) aminohydroxypropylidene bisphosphonate and was absent in the patients who showed no temperature rise. In the group treated intravenously this had no effect on subsequent values of urinary hydroxyproline, which decreased similarly in All differences significant (p<0-01).
patients with and without a temperature response. In the oral treatment group, however, those patients in whom no rise in temperature had occurred had a slower rate of decrease of urinary hydroxyproline; this difference was significant from day 4 onwards (p<OO0l In the second modality oral treatment was stopped not after return to normal of the serum alkaline phosphatase activity but after return to normal of urinary hydroxyproline excretion, which occurred two to three months earlier ("short term" oral treatment). This group had 28 patients and treatment ranged from two weeks to nine months (median one month). All these patients had a return to normal of their urinary hydroxyproline excretion, and in 25 cases (89%) serum alkaline phosphatase activities subsequently decreased to normal (table II). The remaining three patients showed a considerable fall in serum alkaline phosphatase activity (from a mean of 186 to 70 U/1).
The third treatment modality consisted of daily infusions of 20 mg aminohydroxypropylidene bisphosphonate for 10 consecutive days. There were 32 patients in this group, and in 27 of them urinary hydroxyproline excretion became normal by day 9. In the other five it decreased from 3020 (SEM 928) to 860 (222) pmol/24 hours. There was no further decrease in urinary hydroxyproline excretion after the infusion was stopped. In the 27 patients in whom hydroxyproline excretion fell to normal serum alkaline phosphatase activity continued to decrease after the end of treatment and subsequently became normal in nearly all (in 26 of 27 cases in two weeks to six months, median three months). In the five patients, however, in whom urinary hydroxyproline excretion had not become normal by the end of treatment serum alkaline phosphatase activity plateaued at raised levels. Additional oral treatment with aminohydroxypropylidene bisphosphonate resulted in further reductions in serum alkaline phosphatase activity and urinary hydroxyproline excretion and return to normal values in two. These two cases are included in the assessment of overall efficacy but not in the actuarial analysis. Figure 3 shows the individual responses ofthe serum alkaline phosphatase activity in all 142 patients. Values after treatment refer to those either immediately after the end of long term oral treatment or four to six months after completion of both short term treatments. In 129 cases (91%) serum alkaline phosphatase activities had returned to normal. One year later 91 patients (64%) still had normal serum alkaline phosphatase values. During the year 12 patients (11 with normal, one with raised serum alkaline phosphatase activities after treatment) were lost to follow up.
Mode oftreatment and duration ofremission
Remission begins with the induction ofnormal serum alkaline phosphatase activity; this occurred in 129 patients. Recurrence starts the first time that the serum alkaline phosphatase activity exceeds the upper limit of normal. oral treatment, bisphosphonates, including aminohydroxypropylidene bisphosphonate, are poorly absorbed from the intestine and the high doses required for full effect may be associated with gastrointestinal complaints. Hence it is important to explore alternative modes of delivery. This was made possible by the establishment of criteria for the efficacy of aminohydroxypropylidene bisphosphonate based on analysis ofthe fractional decrease of the initial excess of urinary hydroxyproline excretion in relation to the decrease in serum alkaline phosphatase values which invariably ensued.8 In this way short term regimens with either oral or intravenous aminohydroxypropylidene bisphosphonate could be tried. Our studies confirmed that in order to obtain a complete remission with return to normal of the serum alkaline phosphatase activity it was first essential to get the urinary hydroxyproline excretion back to normal. With oral aminohydroxypropylidene bisphosphonate it is not necessary to prolong treatment beyond the time at which urinary hydroxyproline excretion returns to normal. Intravenous treatment is certainly more efficacious than oral, but a 10 day course is too short to obtain remission in all patients. This is related to the kinetics of urinary hydroxyproline excretion after treatment with aminohydroxypropylidene bisphosphonate, as the rate of fall is similar for all degrees of activity and independent of initial values. Thus in patients with high activity of the disease the short intravenous course must be followed with oral aminohydroxypropylidene bisphosphonate.
Intestinal absorption of aminohydroxypropylidene bisphosphonate is about 1% of the dose and the median time required to obtain normal urinary hydroxyproline excretion with short term oral treatment is one month. Hence the amount of aminohydroxypropylidene bisphosphonate delivered with this regimen is very similar to that delivered by intravenous treatment for 10 days, suggesting that the total dose in relation to a minimal number of lesions is important for obtaining a remission. Nevertheless, the duration of remission seems to depend more on the degree of suppression of activity of the disease than on the total amount of bisphosphonate given, as insufficient, though nearly complete, sup-pression leads to rapid recurrence which responds to retreatment8 (unpublished observations).
The suppressive effect of aminohydroxypropylidene bisphosphonate on the activity of the disease may be long lasting, which contrasts with the experience with calcitonins: with these agents the effect is lost completely within a year.5 Direct comparisons with the other second generation bisphosphonate more commonly used in clinical practice (dichloromethylene bisphosphonate; Cl2MDP) are not possible, mainly owing to the lack of published data on normalisation of serum alkaline phosphatase activities with its use and the clearly higher doses employed.'617 It should also be noted that these two bisphosphonates inhibit osteoclastic resorption by different mechanisms: aminohydroxypropylidene bisphosphonate blocks the accession of osteoclast precursors to bone, whereas dichloromethylene bisphosphonate interferes with the function of mature osteoclasts. 18 In this series the rapid inhibitory effect of aminohydroxypropylidene bisphosphonate on bone resorption was shown by the fall in urinary hydroxyproline excretion and serum and urinary calcium concentrations. This was of higher magnitude with intravenous than with oral treatment but the dose delivered in the circulation with the first mode was also higher. Interestingly, during the first 24 hours of treatment with both oral and intravenous aminohydroxypropylidene bisphosphonate about half the patients had an increase in urinary hydroxyproline excretion. These were the patients who also showed transient temperature rises and haematological changes. We have previously shown these transient changes in a small group of patients treated with oral aminohydroxypropylidene bisphosphonate,'9 and they have also been reported with other aminobisphosphonates."0 The occurrence of these changes in the same proportion of patients whether treated by mouth or intravenously shows clearly that they are not related to differences in absorption with the oral preparations and suggests a direct or indirect effect of this bisphosphonate on the mononuclear phagocyte system, possibly through release of lymphokines or cytokinins. We know, for example, that interleukin 1 may increase bone resorption in vitro and may also induce haematological changes similar to those noted in this study.2'22 Such changes, however, are never seen in patients who have previously received aminohydroxypropylidene bisphosphonate (unpublished observations), and the early decrease of urinary hydroxyproline is much less in patients with no temperature rise. Possibly, therefore, these transient phenomena are related to the mechanism of action of aminohydroxypropylidene bisphosphonate. We have shown that aminohydroxypropylidene bisphosphonate has no direct effect on osteoclast precursors, which share the same origin with the macrophage system, but that its action on the bone matrix alters its ability to induce transformation of precursor into mature osteoclasts.'" ' This suggests that the induction of this transient response is due to an indirect action of aminohydroxypropylidene bisphosphonate on osteoclast precursors through a mechanism entailing recognition of bone matrix by the bisphosphonate. This, however, warrants further investigation.
The side effects ofaminohydroxypropylidene bisphosphonate are due to local irritation, which may be particularly troublesome with the oral preparations. The effect is dose related and very rarely seen in patients given 300 mg/day or less. Conversely, daily doses higher than 600 mg are poorly tolerated by most patients.
Treatment of Paget's disease of bone must aim at maximal suppression of serum alkaline phosphatase values to within the normal range. This can best be achieved by short term intravenous aminohydroxypropylidene bisphosphonate in most patients. If the activity of the disease is high this regimen must be supplemented with oral aminohydroxypropylidene bisphosphonate at a dose which does not cause gastric irritation. In this way complete and longlasting remissions can be obtained. 
YEARS AGO
The police at Birkenhead appear to take a more comprehensive view oftheir duties than they do in other places, notably in London. Last week the magistrate was called upon to settle a point which is certainly not devoid of interest for the inhabitants of towns; namely, as to the way in which workmen are at liberty to carry their tools through the street when walking on the footpath. In this particular case a coalheaver was summoned for carrying a spade with the blade projecting over his shoulder. The case was dismissed as the magistrate was not satisfied that the public had really been exposed to risk of injury. It is quite possible that in this instance the prosecution was not well advised, but the question merits attention. The careless way in which workmen carry pointed, cutting or other dangerous tools along public thoroughfares is by no means rarely the cause ofaccidental wounds. A carpenter who carries a saw, projecting out of the bag slung over his back, has been the involuntary cause ofa serious scalp wound to a passerby, and injuries resulting from collision with planks, iron bars, and so forth, are of extremely common occurrence. Not long since, a workman in Paris took with him on the tramcar a keg of sulphuric acid, which he managed to break, inflicting terrible injuries on himself, his fellow passengers, and the horses. A man has no more right to carry a tool to the common danger, than he has to twirl his stick or umbrella round at the risk of abrading or removing an eye or upper lip. (Brirish Medicaljow-nal 1887;i:894.)
